Cerebrovasc Dis 2008, 25:170–175.CrossRefPubMed 26. Yetkin G:Chlamydia pneumoniae and coronary artery disease: controversial results of serological studies. Int Immunopharmacol 2006, 6:1524–1525.CrossRefPubMed 27. Liuba P, Pesonen E: Infection and early atherosclerosis: does the evidence support causation? Acta Paediatr 2005, 94:643–651.CrossRefPubMed 28. Kalayoglu MV, Indrawati, Morrison RP, Morrison SG, Yuan Y, Byrne GI: Chlamydial virulence determinants
in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect Dis 2000,181(Suppl 3):S483–489.CrossRefPubMed Selleckchem S3I-201 29. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135–1143.CrossRefPubMed 30. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45:1169–1196.CrossRefPubMed 31. Bobkova D, Honsova E, Kovar J, Poledne R: Effect of diets on lipoprotein concentrations in heterozygous apolipoprotein E-deficient mice. Physiol Res 2004, 53:635–643.PubMed 32. Jawieñ J,
Nastałek P, Korbut R: Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004, 55:503–517.PubMed 33. Higuchi ML, Santos MH, Roggério A, Kawakami JT, Bezerra HG, Canzian M: A role for archaeal organisms in development of atherosclerotic vulnerable plaques and myxoid matrices. Clinics 2006, 61:473–478.CrossRefPubMed 34. NRC. National Research Council: Guide for the care and use of laboratory animals. National Academic JQ1 Press. Washington. DC 35. Kenny GE: Serodiagnosis. Mycoplasmas Molecular Biology and Pathogenesis (Edited by: McElhaney RN, Finch LR, Baseman JB). Washington:American Society for Microbiology 1991, 505–512. 36. Reynolds ES: The use of lead citrate at high pH as an electron-opaque stain in electron microscope. J Cel Biol 1963, 17:208–212.CrossRef 37. Davies G, Reid L: Growth of the alveoli and pulmonary
arteries in childhood. Thorax 1970, 25:669–681.CrossRefPubMed 38. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ: Compensatory enlargement of human atherosclerotic ROS1 coronary arteries. N Engl J Med 1987, 316:1371–1375.CrossRefPubMed 39. Nishioka T, Berglund H, Luo H, Nagai T, Siegel RJ: How should we define inadequate coronary arterial remodeling. Circulation 1998, 97:1424–1425.PubMed Authors’ contributions SBD and MLH – carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. MMR and MLH – participated in the design of the study and performed the statistical analysis. JTO; SAPP; RNI and LFPF – participated in the sequence alignment. MHL – conceived of the study, and participated in its design and coordination and helped to draft the manuscript. JT and FCP – carried out the immunoassays.